Keywords: Orphan drugs, Designation, Pricing, Funding, Japan, South Korea, Taiwan, Singapore, Australia

Orphan drugs in Asia-Pacific: From designation to pricing, funding and market access

Article | 8 February 2010

• Print This

It is estimated that 6%-10% of the world’s population will suffer from a rare disease at one point in life. On this basis, the markets of Asia-Pacific should offer great potential to companies developing orphan drugs. The region’s population is four billion, nearly two-thirds of the global total, so even the rarest disease will have many patients seeking treatment.

But clinical need rarely correlates with affordability, which dictates what is actually spent on health care. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.